Barry L Shulkin, MD
Disclosures: Nothing to disclose - 08/18/2022
OMB No. 0925-0046, Biographical Sketch Format Page



OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)


Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.


eRA COMMONS USER NAME (credential, e.g., agency login):


EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)



(if applicable)


Completion Date





University of Texas, Austin




University of Texas Southwestern Medical School, Dallas




University of Michigan School of Business, Ann Arbor





  1. Personal Statement


In the past year I mentored a medical student.  I had taken a few years off from participation due to other demands.  The experience was very rewarding both on a personal and professional basis.  My trainee researched in depth a particular medical issue relevant to pediatric oncology and bone marrow transplantation.  This will result in both an abstract to a professional meeting and a peer reviewed manuscript.  The experience has revitalized my enthusiasm for teaching and for interacting with the bright, motivated students.  My most recent trainee will be competitive for residency and internship programs of his choice.   This program has resulted in several long term professional relationships for me with POE students and is very rewarding for the impact it makes upon the student and particularly for me to witness the long term successful development of the students into highly regarded physicians.



  1. Positions and Honors


Positions and Employment


07/1996-12/1996              Senior Postdoctoral Training, Visiting Associate Professor, Harvard Medical School,

              Department of Radiology, Brigham and Women's Hospital, Boston, MA

1978-1979              Internal Medicine Intern, University of Texas Southwestern Affiliated Hospitals (Parkland Memorial Hospital and Dallas Veterans Administration Medical Center), Dallas, TX

1979-1981              Internal Medicine Resident, University of Texas Southwestern Affiliated Hospitals (Parkland Memorial Hospital and Dallas Veterans Administration Medical Center), Dallas, TX

1981-1984              Endocrinology Fellow; University of North Carolina School of Medicine, Chapel Hill, NC (preceptor:  Robert D. Utiger, MD)

1984-1986              Nuclear Medicine, University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, MI

07/1986-08/1992              Assistant Professor, University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, MI

09/1992-08/1999              Associate Professor, University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, MI

1999-2004              Professor, University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, MI

1986-2004              Director, Pediatric Nuclear Medicine Satellite Clinic, Mott Children's Hospital, University of Michigan Medical Center

2002-2004              Acting Chief, Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical Center, Ann Arbor, MI

2004-present              Member, Division of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children’s Research Hospital, Memphis, TN


Other Experience and Professional Memberships

              Phi Beta Kappa

              Alpha Omega Alpha

              Society of Nuclear Medicine and Molecular Imaging

              American College of Physicians

              Endocrine Society

              American Thyroid Association

              European Association of Nuclear Medicine

              Society for Pediatric Radiology

              Children's Oncology Group             

              Board of Directors:  American Board of Nuclear Medicine; January 2004 – January 2011

              Chairman, American Board of Nuclear Medicine: January 2010- January 2011


  1.         Contributions to Science


  1.          My early contributions as a fellow were to further understanding of the mechanism of the deiodination conversion of thyroxine (T4) to triiodothyroinin (T3) and its clinical impact.
  1. Shulkin BL, Utiger RD, Emerson CH, Braverman LE, Fay M.  Pre-incubation of thyroxine with sulfhydryl reducing agents does not stimulate thyroxine inner or outer ring deiodination.  Endocrinology 113:851-854, 1983.
  2. Shulkin BL, Utiger RD.  Reverse triiodothronine does not alter pituitary-thyroid function in man.  J Clin Endocrinol Metab 58:1184, 1984.
  3. Shulkin BL, Utiger RD.  Caloric restriction does not alter thyrotropin secretion in hypothyroidism.  J Clin Endocrinol Metab 60:1076, 1985.
  4. Shulkin BL, Bolger MB, Utiger RD.  Thyroid hormone analog inhibition of hepatic 5'-deiodinase activity.  J Endocrinol Invest 11(9):657-662, 1988.


  1.                                                                 Pheochromocytomas and neuroblastomas are tumors derived from tissue related to the sympathetic nervous sytem.  Although rare, they possess a transporter also common to tissues of the sympathetic nervous system, hNET (the human norepinephrine transporter).  As a result, they may be imaged noninvasively using tracers specifically designed to track tissues related to the sympathetic nervous system.  The first such agent was mIBG (meta-iodobenzylguanidine) now FDA approved and a critical component of the care of patients with pheochromocytoma.  I have participated in both local and nationwide trials using this agent to characterize treatment response.  I continue to actively participate in projects utilizing mIBG for patients with neuroblastoma.             
  1. Shulkin BL, Shapiro B, Hutchinson RJ.  131I-MIBG and bone scintigraphy for the detection of neuroblastoma.  J Nucl Med 33(10):1735-1740, 1992.
  2. Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging 52(4):341-350, 2008.
  3. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of (123) I-metaiodobenzylguanidine (MIBG) and (131) I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 56(7):1041-1045. 2011   PMID: 21328522
  4. Sharp SEE, Parisi MT, Gelfand MJ, Yanik GA, Shulkin BL.  Functional-metabolic imaging of neuroblastoma. Q J Nucl Med Mol Imaging 57(1):6-20, 2013. PMID: 23474631


  1.                                                                 I have contributed further to the evaluation of neuroendocrine tumors using PET (positron emission tomography) tracers.  These tracers localize much more quickly to the tumors and provide superior image quality compared to the conventional imaging agent 123I-mIBG.
  1. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE.  PET scanning with hydroxyephedrine:  An approach to the localization of pheochromocytoma.  J Nucl Med 33(6):1125-1131, 1992.
  2. Shulkin BL, Mitchell DS, Ungar DR, Prakash D, Dole M, Castle VP, Hernandez RJ, Koeppe RA, Hutchinson RJ.  Neoplasms in a pediatric population:  2-[F-18]-Fluoro-2-deoxy-D-glucose PET studies.  Radiology 194:495-500, 1995.
  3. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, Rawhas JB, Castle VP, Sisson JC, Hutchinson RJ.  PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37:16-21, 1996.
  4. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC.  Neuroblastoma: positron emission tomography with 2-[Fluorine-18]Fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.  Radiology 199:743-750, 1996.


  1.                                                                 Most tumors in children are metabolically active, that is they express the glucose transporter which facilitates glucose entry into cells.  FDG (18F-fluorine-2-D-deoxyglucose) is a glucose analog that demonstrates metabolic activity of tumors.  We were the first to utilize this agent for the study of children with neoplastic diseases.  FDG PET is commonly used for the management of children with malignant conditions.  We are also investigating the use of 11C-methionine to characterize the amino acid transport system in patients with pediatric tumors.             
  1. Hossain AKM M, Shulkin BL, Gelfand MJ, Bashir H, Daw NC, Sharp SE, Nadel HR, Dome JS. FDG-positron emission tomography-computerized tomography studies of Wilms’ tumor. Eur J Nucl Med Mol Imaging 37(7):1300-1308, 2010. PMID: 20204356. 
  2. Cheuk DKL, Sabin ND, Hossain AKMM, Wozniak A, Naik M, Rodriguez-Galindo C, Krasin MJ, Shulkin BL. Positron emission tomography-computed tomography for staging and follow-up of pediatric nasopharyngeal carcinoma.  Eur J Nucl Med Mol Imaging 39:1097-1106, 2012. PMC3531235
  3. McCarville MB, Billups CA, Wu J, Kaufman RA, Kaste SC, Coleman JL, Sharp SE, Nadel NR, Charron M, Lederman HM, Don S, Shochat SJ, Daw NC, Shulkin BL. The role of PET-CT in assessing pulmonary nodules in children with solid malignancies.  Am J Roentgenol/AJR 201(6):W900-905, 2013. PMID: 24261397
  4. Harris SM, Davis JC, Snyder SE, Butch ER, Vāvere AL, Kocak M, Shulkin BL.  Evaluation of the biodistribution of [11C]methionine in children and young adults. J Nucl Med 54(11):1902-1908, 2013.  PMC3924715
  5. Ostermeier A, McCarville MB, Navid F, Snyder SE, Shulkin BL.  FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. Pediatr Radiol. 2015 Feb 27. [Epub ahead of print]  PMID: 25721584
  6. Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, Jenkins JJ, Snyder SE, Reddick WE, Santana VM, McCarville MB, Guo J, Shulkin BL.  FDG PET CT Studies in Pediatric Patients with Osteosarcoma:  Comparison of Early and Delayed Imaging with Response to Therapy.  J Nucl Med epublished June 13, 2017  DOI 10.2967 jnumed 117.190595


Complete List of Published Work in MyBibliography:


  1.         Additional Information:  Research Support and/or Scholastic Performance


Ongoing Research Support





Completed Research Support


5 U01CA081457-15 PBTC Boyett (Broniscer)               4/4/2002 - 3/31/2014              



Provide support for continued PBTC participation


5 U10CA098543-11 (CHOP SUB) (Shulkin)               7/7/2003 - 2/28/2014              


Children's Oncology Group (COG) Chair Grant - Diagnostic Imaging Review

Reviewer COG Protocols ANBL0032, A3973, and ANBL0321.